Date: Sep 26, 2013 Source: Randon-Research.org (
click here to go to the source)
Tansna Therapeutics is in the market with a $850,000 non-brokered equity offering. The offering is expected to close within a year. Tansna Therapeutics didn't close any previous offering on the US private placement market however the company received investments from the pre-seed Spark Fund and the Missouri Technology Corp. according to the St. Louis Business Journal.
Tansna is a drug research and development company focusing on discovering and commercializing oral drugs to treat epilepsy. It has discovered novel compounds that are highly effective in several animal models of epilepsy, including refractory epilepsy. According to the company, nearly 1 in 26 people will develop epilepsy in their lifetime.
The company is headquartered in St. Louis MO. No revenues were reported for the latest fiscal year.
The executive team includes George Capps, Robert Karr and Alan Macinnes. The board of directors includes Max Baker, Charles Bolten and Rajesh Devraj.
Offering recap:
Status: Launched
Company: Tansna Therapeutics
Industry: Biotechnology
Amount offered: $850,000
Amount placed: $0
